These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19377280)

  • 1. Identification of a tumor associated antigen that can induce tumor specific cytotoxicity.
    Dunkle A; He YW
    Cancer Biol Ther; 2009 May; 8(9):844-5. PubMed ID: 19377280
    [No Abstract]   [Full Text] [Related]  

  • 2. [Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].
    Imai N; Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2125-9. PubMed ID: 23259384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining tumor antigens: mRNA, protein or cytotoxicity?
    Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
    Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
    [No Abstract]   [Full Text] [Related]  

  • 4. [The function of tumor specific antigen (MAGE) in tumor immunotherapy].
    Fang JB; Wang L
    Sheng Li Ke Xue Jin Zhan; 2005 Jul; 36(3):273-5. PubMed ID: 16270835
    [No Abstract]   [Full Text] [Related]  

  • 5. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
    Gaugler B; Olive D
    Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC-binding peptides as immunotherapeutics for cancer.
    Kobayashi H; Kennedy R; Lu J; Davila E; Celis E
    Immunol Invest; 2000 May; 29(2):105-10. PubMed ID: 10854176
    [No Abstract]   [Full Text] [Related]  

  • 8. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview.
    Shinitzky M; Skornick Y
    Prog Clin Biol Res; 1990; 348():95-125. PubMed ID: 2201036
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor immunology.
    Stevenson H; Tsang KY
    Immunol Ser; 1993; 58():497-515. PubMed ID: 8424991
    [No Abstract]   [Full Text] [Related]  

  • 12. Strategies for immunotherapy of cancer.
    Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
    Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
    [No Abstract]   [Full Text] [Related]  

  • 13. T351 protein, a novel tumor associated antigen and potential target for immunotherapy.
    Lu J; Kang N; Cui L; Ba D; Cheng S; He W
    Cancer Biol Ther; 2009 May; 8(9):835-43. PubMed ID: 19270507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of melanoma antigen expression in cancer therapy.
    Gillespie AM; Coleman RE
    Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
    Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
    Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibilities for active immunotherapy of human cancer.
    Hellström KE; Hellström I
    Cancer Invest; 1992; 10(4):285-93. PubMed ID: 1378351
    [No Abstract]   [Full Text] [Related]  

  • 17. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor immunology.
    Naftzger C; Houghton AN
    Curr Opin Oncol; 1991 Feb; 3(1):93-9. PubMed ID: 2043699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.